Last updated: September 4, 2026
Latrepirdine, also known as dimebon, is an abandoned neurodegenerative-disease drug candidate. Its late-stage Alzheimer’s disease and Huntington’s disease programs failed to demonstrate meaningful clinical benefit. Pfizer and Medivation discontinued development, and latrepirdine has no FDA approval, no Orange Book listing, no established generic market, and no credible near-term commercial revenue forecast.
What is the current development status of latrepirdine?
Latrepirdine development is inactive. No active FDA registration program, commercial launch plan, or late-stage clinical program has been publicly established.
| Item |
Status |
| Active ingredient |
Latrepirdine hydrochloride, also called dimebon |
| Drug type |
Oral small molecule |
| Original use |
Antihistamine marketed in Russia and certain former Soviet markets |
| Main development target |
Alzheimer’s disease |
| Other clinical targets |
Huntington’s disease, Parkinson’s disease, amyotrophic lateral sclerosis |
| FDA approval |
None |
| EMA approval |
None for neurodegenerative indications |
| Orange Book listing |
None |
| Current commercial product |
None identified |
| Lead development companies |
Medivation and Pfizer |
| Development outcome |
Discontinued after failed Phase 3 studies |
Latrepirdine attracted interest after a small randomized Alzheimer’s disease study reported improvements in cognition and global function. A subsequent Phase 3 program failed to reproduce those results. The compound was also tested in Huntington’s disease, where it failed to improve the primary clinical endpoint.
What clinical trials caused latrepirdine development to fail?
The Alzheimer’s disease program failed in large Phase 3 studies. The Huntington’s disease program also failed in Phase 3.
Alzheimer’s disease trials
A 2008 Phase 2 study published in The Lancet enrolled 183 patients with mild-to-moderate Alzheimer’s disease. Over six months, patients receiving dimebon showed statistically significant improvements on several cognitive and functional measures compared with placebo (Doody et al., 2008).
The result led Medivation and Pfizer to expand development into large Phase 3 trials. The principal studies were:
| Trial |
Disease |
Approximate enrollment |
Outcome |
| CONNECTION |
Mild-to-moderate Alzheimer’s disease |
598 |
Failed primary efficacy endpoints |
| CONCERT |
Mild-to-moderate Alzheimer’s disease |
Approximately 1,000 |
Failed to confirm clinical benefit |
The CONNECTION trial did not meet its co-primary endpoints based on cognition and global function. Medivation reported that the results did not support continued development in Alzheimer’s disease (Medivation, 2010).
The CONCERT study produced the same strategic result. After the Phase 3 failures, the development case for latrepirdine in Alzheimer’s disease collapsed. The earlier positive Phase 2 findings were generally viewed as non-replicated in larger, more rigorous studies.
Huntington’s disease trial
The HORIZON study evaluated latrepirdine in patients with Huntington’s disease. The trial enrolled roughly 400 patients and assessed cognition, behavior, motor function, and global clinical status.
HORIZON failed to show improvement on its primary endpoint. The result weakened the rationale for continuing latrepirdine across additional neurodegenerative indications.
Other indications
Latrepirdine was investigated in Parkinson’s disease and amyotrophic lateral sclerosis. These programs did not generate a successful registration package or a commercial product. No clinical evidence has established latrepirdine as an effective treatment in any major neurodegenerative indication.
When did Pfizer and Medivation discontinue latrepirdine?
Pfizer and Medivation discontinued the Alzheimer’s disease collaboration after the negative Phase 3 results in 2010. The companies had entered a development and commercialization agreement in 2008. Pfizer paid Medivation an upfront amount reported at approximately $225 million, with additional potential milestone payments and shared development responsibilities.
The termination removed the financial and operational infrastructure behind the global Alzheimer’s program. Medivation subsequently stopped further development activities after the negative results from the Alzheimer’s and Huntington’s programs.
| Date |
Event |
| 2008 |
Medivation and Pfizer enter a global development and commercialization collaboration |
| 2008 |
Positive Phase 2 Alzheimer’s data generate substantial market interest |
| 2010 |
CONNECTION Alzheimer’s Phase 3 study fails |
| 2010 |
HORIZON Huntington’s disease study fails |
| 2010 |
Pfizer and Medivation discontinue the collaboration |
| 2011-2012 |
Further clinical development is abandoned |
| 2024 |
No FDA-approved latrepirdine product or active late-stage program |
What is the FDA regulatory status of latrepirdine?
Latrepirdine has never received FDA approval. The agency has not approved it for Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, ALS, or another indication.
The lack of approval has several consequences:
- There is no FDA-approved label.
- There is no New Drug Application with approved indications that could support generic filing.
- There is no statutory Hatch-Waxman exclusivity period.
- There is no Orange Book-listed reference product.
- There is no conventional Paragraph IV litigation pathway against an approved latrepirdine product.
Latrepirdine’s historical availability as an antihistamine in Russia does not create U.S. approval rights. A sponsor seeking to revive the molecule in the United States would need to establish an acceptable regulatory pathway, including new clinical evidence sufficient to support an NDA.
What patents protect latrepirdine?
Latrepirdine’s commercial patent position is weak because the molecule is old, the principal development programs ended more than a decade ago, and no FDA-approved product has generated a current Orange Book patent estate.
The relevant intellectual-property categories are:
| Patent category |
Commercial relevance |
| Original compound patents |
Likely expired or approaching the end of practical commercial life, depending on jurisdiction and filing date |
| Salt and formulation patents |
Potentially relevant only if valid, unexpired, and supported by a new product |
| Alzheimer’s method-of-use patents |
Limited value after failed Phase 3 development |
| Huntington’s method-of-use patents |
Limited value after failure of the HORIZON study |
| Manufacturing patents |
Could affect process control, but do not create a proven commercial franchise |
| Orange Book patents |
None associated with an FDA-approved latrepirdine product |
No reliable commercial conclusion should be based on a historical patent filing alone. A patent may be expired, abandoned, narrowed during prosecution, invalidated, or limited to a formulation or method that has no demonstrated clinical value.
How strong is the latrepirdine patent estate?
The patent estate is commercially weak.
The principal weakness is not only patent age. It is the absence of a validated product. Even an unexpired formulation or method-of-use patent would have limited economic value without:
- a sponsor willing to restart development;
- a clinically credible indication;
- a regulatory filing strategy;
- freedom to operate around prior patents;
- manufacturing capability; and
- evidence that the new formulation or use improves clinical outcomes.
Because no approved latrepirdine product exists, there is no Orange Book-based patent barrier protecting an incumbent market.
Are there Paragraph IV challenges or generic-entry risks?
There are no meaningful Paragraph IV challenges directed at latrepirdine because no FDA-approved reference product exists.
Generic-entry risk is therefore structurally different from the risk associated with approved drugs:
| Risk category |
Latrepirdine assessment |
| ANDA launch against an approved reference product |
Not applicable |
| Paragraph IV certification |
Not applicable absent an approved reference product |
| Generic substitution |
None |
| 505(b)(2) competition |
Possible if a sponsor develops a new formulation or indication |
| Off-label imported use |
Limited and commercially unstructured |
| New molecular sponsor entry |
Requires renewed clinical and regulatory investment |
A future sponsor could potentially pursue a 505(b)(2) application for a new formulation or rely on selected prior data, but the failed Phase 3 record would make a streamlined development strategy difficult. The sponsor would likely need to address efficacy directly rather than rely on historical Phase 2 findings.
What formulations are protected by latrepirdine patents?
Latrepirdine was principally developed as an oral drug, including tablet formulations. Publicly available development history does not establish a commercially important extended-release, injectable, transdermal, implantable, or other differentiated delivery system.
Potential formulation claims could include:
- latrepirdine hydrochloride;
- solid oral dosage forms;
- stability-enhanced tablets;
- controlled-release formulations;
- combination products; and
- formulations designed to improve tolerability or pharmacokinetics.
These categories do not establish current protection. Their value depends on issued claims, expiration dates, maintenance status, jurisdiction, and clinical differentiation. No formulation has reached FDA-approved commercial status.
What patent litigation affects latrepirdine?
No significant U.S. patent litigation involving an approved latrepirdine product is established in the public commercial record.
The absence of litigation is consistent with the product’s status:
- no FDA-approved reference drug;
- no Orange Book listings;
- no active generic launch program;
- no current branded commercial market;
- no commercially important patent dispute between an innovator and ANDA applicant.
Any historical patent disputes involving development rights, ownership, or prosecution would be distinct from the generic patent litigation commonly associated with marketed drugs.
What is the market projection for latrepirdine?
The base-case market projection is zero near-term revenue.
Latrepirdine has no approved indication, no marketed product, no reimbursed position, and no active development sponsor with a disclosed launch timeline. A commercial forecast based on the historical Alzheimer’s market opportunity would overstate the asset’s current value.
| Projection period |
Base-case outlook |
| 2024-2025 |
No meaningful commercial revenue |
| 2026-2028 |
No credible launch absent a new sponsor and clinical program |
| Longer term |
Highly contingent on redevelopment and positive Phase 2/3 evidence |
The historical addressable market was large. Alzheimer’s disease affects millions of patients globally, and disease-modifying and symptomatic therapies have attracted substantial investment. That market size does not translate into a latrepirdine forecast because the compound failed in late-stage trials and lacks regulatory approval.
What would be required for a commercial relaunch?
A relaunch would require more than reformulation. A sponsor would need to establish:
- a defensible intellectual-property position;
- a clinically differentiated mechanism or biomarker strategy;
- a new target indication;
- a regulatory agreement with the FDA;
- controlled clinical evidence;
- scalable manufacturing; and
- a reimbursement and commercial strategy.
A new formulation could extend patent life only if it produced a patentable and clinically meaningful product. Formulation patents alone would not repair the historical efficacy failure.
How does latrepirdine compare with competing Alzheimer’s drugs?
Latrepirdine is commercially weaker than approved Alzheimer’s therapies because it has no label, no validated clinical benefit, and no regulatory exclusivity.
| Drug or class |
Regulatory position |
Disease role |
Latrepirdine comparison |
| Donepezil |
FDA approved |
Symptomatic treatment |
Established generic and branded history |
| Memantine |
FDA approved |
Symptomatic treatment |
Established generic market |
| Lecanemab |
FDA approved under accelerated approval pathway |
Amyloid-directed disease modification |
Positive late-stage evidence and commercial launch |
| Donanemab |
FDA approved in 2024 |
Amyloid-directed disease modification |
Regulatory and commercial infrastructure |
| Latrepirdine |
Not approved |
No established role |
Failed Phase 3 development |
Lecanemab and donanemab also carry substantial monitoring, diagnostic, and safety requirements. Those burdens do not create an opportunity for latrepirdine unless it demonstrates a clear clinical advantage, which has not occurred.
What is the geographic coverage of latrepirdine rights?
Latrepirdine had historical use in Russia and certain former Soviet markets as an antihistamine. Its neurodegenerative-disease development was conducted through international clinical programs involving Medivation and Pfizer.
There is no current global commercial footprint comparable with a marketed innovative medicine. Patent and regulatory rights must be evaluated jurisdiction by jurisdiction, but the practical commercial position is constrained by:
- the age of the compound;
- the failure of international Phase 3 programs;
- the absence of FDA or European approval;
- the lack of a current commercial sponsor; and
- the probable expiration of core composition protection.
Key Takeaways
- Latrepirdine, or dimebon, is an abandoned neurodegenerative drug candidate.
- The compound failed the CONNECTION and CONCERT Alzheimer’s disease studies.
- It also failed the HORIZON Huntington’s disease trial.
- Pfizer and Medivation discontinued development after the late-stage failures.
- Latrepirdine has no FDA approval, Orange Book listing, approved label, or Hatch-Waxman exclusivity.
- No meaningful Paragraph IV or generic-launch risk exists because no reference product is approved.
- The historical patent position has limited commercial value without a new clinical and regulatory program.
- The base-case market projection is zero near-term revenue.
- Any future value would depend on a new sponsor, a differentiated indication or formulation, and successful clinical redevelopment.
FAQs
Is latrepirdine still being developed for Alzheimer’s disease?
No. The major Alzheimer’s disease program ended after negative Phase 3 results, and no active late-stage development program has been publicly established.
Was latrepirdine ever approved in the United States?
No. Latrepirdine has never received FDA approval for Alzheimer’s disease, Huntington’s disease, or another indication.
Can a generic company launch latrepirdine?
Not through the normal ANDA pathway against an approved latrepirdine reference product. There is no FDA-approved reference product or Orange Book listing.
Did latrepirdine show efficacy in early clinical trials?
Yes. A Phase 2 Alzheimer’s disease study reported positive cognitive and functional results, but larger Phase 3 studies failed to confirm the benefit.
Does latrepirdine have residual licensing value?
Residual value is likely limited. A buyer would face substantial clinical redevelopment, regulatory, manufacturing, and intellectual-property risks without an established commercial product.
References
-
Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L., & Hung, D. (2008). Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: A randomised, double-blind, placebo-controlled study. The Lancet, 372(9634), 207-215. https://doi.org/10.1016/S0140-6736(08)61074-0
-
Medivation, Inc. (2010). Medivation and Pfizer announce topline results from CONNECTION trial of dimebon in Alzheimer’s disease. Company press release.
-
Medivation, Inc. (2010). Medivation and Pfizer discontinue development of dimebon in Alzheimer’s disease. Company press release.
-
Pfizer Inc. (2008). Pfizer and Medivation announce worldwide collaboration for dimebon. Company press release.
-
U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: Dimebon clinical studies. ClinicalTrials.gov. https://clinicaltrials.gov
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/